Nobilon receives European GMP approval for production of Influenza vaccines for clinical trials
After completing in vitro and toxicological testing, the next phase of development will be to determine the safety and efficacy of Nobilon's flu vaccine in humans. For this purpose clinical vaccine batches need to be produced under GMP. Nobilon employs a novel vaccine production system which uses large scale cell culture technology in 2000 liter fermentors, as opposed to the traditional method of using commercial embryonated chicken eggs. This advanced technology is more reliable and results in pure, safe and efficacious vaccines with constant quality. Furthermore, in the event of a pandemic bird flu outbreak, Nobilon's cell culture production can be used immediately in contrast to the traditional production system based on chicken eggs which needs a significant logistical coordination and could lead to eggs becoming unavailable.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.
Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.